Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
998.46B
Market cap998.46B
Price-Earnings ratio
46.12
Price-Earnings ratio46.12
Dividend yield
0.57%
Dividend yield0.57%
Average volume
3.22M
Average volume3.22M
High today
$1,054.58
High today$1,054.58
Low today
$1,015.23
Low today$1,015.23
Open price
$1,047.29
Open price$1,047.29
Volume
85.67K
Volume85.67K
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 998.46B, Eli Lilly(LLY) trades at $1,046.70. The stock has a price-to-earnings ratio of 46.12 and currently yields dividends of 56.7%.

On 2026-02-24, Eli Lilly(LLY) stock moved within a range of $1,015.23 to $1,054.58. With shares now at $1,046.70, the stock is trading +3.1% above its intraday low and -0.7% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 85.67K, versus its average volume of 3.22M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

MarketWatch 1h
Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

Ozempic's list price is due to get cut, according to a report. Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are co...

Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan
TipRanks 1h
Novo Nordisk to reduce Ozempic, Wegovy list prices by up to 50%, WSJ reports

Novo Nordisk (NVO) plans to cut U.S. list prices for Wegovy and Ozempic by up to half, effective January 1, 2027, The Wall Street Journal’s Peter Loftus reports...

TipRanks 3h
Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership

Asad Haider, an analyst from Goldman Sachs, maintained the Buy rating on Eli Lilly & Co. The associated price target remains the same with $1,260.00. Asad Haid...

Analyst ratings

79%

of 33 ratings
Buy
78.8%
Hold
18.2%
Sell
3%

More LLY News

TipRanks 16h
Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation

Ventyx Biosciences ( (VTYX) ) just unveiled an announcement. On January 7, 2026, Ventyx entered into a merger agreement under which Eli Lilly and Company will...

The Wall Street Journal 21h
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen

The company said the drug will be available at the same self-pay price in either the multi-dose pen or single-dose vial format, starting at $299 a month. brenda...

Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen
Benzinga 22h
Novo Nordisk's Loss Is Eli Lilly's Gain

Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight...

Novo Nordisk's Loss Is Eli Lilly's Gain
The Motley Fool 22h
Why Eli Lilly Stock Just Popped

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly). Eli Lilly (LLY +5.33%) stock, maker of th...

Why Eli Lilly Stock Just Popped
TipRanks 1d
Eli Lilly’s Zepbound now available in multi-dose KwikPen

Eli Lilly (LLY) announced the FDA approved a label expansion for Zepbound to include the four-dose single-patient use KwikPen that delivers a full month of trea...

CNBC 1d
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Eli Lilly on Monday launched a new form of its blockb...

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Barron's 1d
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s All Down to This Weight-Loss Drug Trial.

Biotech and Pharma Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s All Down to This Weight-Loss Drug Trial. In this article NVO LLY Novo Nordisk said on Mo...

Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s All Down to This Weight-Loss Drug Trial.

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.